Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.61 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.59 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1957356 | 0.84 | SMN1; SMN2 (0.71) | MAOBNR4A2PARP10SMN1; SMN2ALOX5 | |
| SCHEMBL4429942 | 0.81 | NR4A2 (0.71) | MAOBNR4A2PARP10APPFFAR1 | |
| SCHEMBL4421947 | 0.81 | MAOB (0.60) | MAOBNR4A2PARP10SMN1; SMN2APP | |
| SCHEMBL4432738 | 0.80 | MAOB (0.71) | MAOBNR4A2PARP10APPMAOA | |
| SCHEMBL4477658 | 0.79 | SMN1; SMN2 (0.63) | SMN1; SMN2 | |
| SCHEMBL4426846 | 0.79 | MAOB (0.61) | MAOBNR4A2PARP10SMN1; SMN2APP | |
| SCHEMBL1958617 | 0.79 | SMN1; SMN2 (0.67) | SMN1; SMN2 | |
| SCHEMBL27550091 | 0.78 | MAOB (0.80) | MAOBNR4A2PARP10APPCA12 | |
| SCHEMBL6415804 | 0.78 | MAOB (0.64) | MAOBNR4A2PARP10APPMAOA | |
| SCHEMBL22874653 | 0.77 | MAOB (0.67) | MAOBNR4A2PARP10APPMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1761480-B1 | MAO-B INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-02-18 | — | — | EP | disclosed |
| US-7253318-B2 | Benzyloxy derivatives as MAOB inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1761480-A2 | NEW MAO-B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006000324-A2 | NEW MAO-B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-05 | — | — | WO | disclosed |
| US-20050288367-A1 | Benzyloxy derivatives as MAOB inhibitors | HOFFMAN-LA ROCHE INC. | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288367-A1 | Benzyloxy derivatives as MAOB inhibitors | MAOB, MAOA, COMT | MAOB 1/4885NR4A2 1668/4885PARP10 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.